(GENI) Generic Sweden publ - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0001790791

GENI: Messaging, APIs, Communication, Platforms, Consulting

Generic Sweden AB (publ) is a Stockholm-based technology company specializing in advanced messaging and digital communication solutions. Since its establishment in 1993, the company has focused on delivering scalable and secure platforms for various applications, catering to both enterprise and consumer markets. Its services include messaging APIs, cloud-based communication tools, and customizable digital platforms designed to streamline interactions. The company operates with a strong emphasis on innovation and reliability, positioning itself as a key player in Swedens tech sector.

Ticker Symbol: GENI | Exchange: ST | Type: Common Stock | Country Origin: Sweden | GICS Sub Industry: IT Consulting & Other Services

From a technical standpoint, GENI is currently trading at 60.80 SEK, above its short-term (SMA 20: 57.88) and medium-term (SMA 50: 57.90) moving averages, signaling bullish momentum. The stock is also well above its long-term SMA 200 (50.87), indicating sustained upward pressure. Average trading volume over the past 20 days has been moderate at 15,624 shares, with an ATR of 1.92, reflecting relatively stable price movements.

Fundamentally, Generic Sweden AB has a market capitalization of 715.39M SEK, with a trailing P/E ratio of 25.53, suggesting investors expect significant future growth. The P/B ratio of 12.60 indicates a premium valuation relative to book value, while the P/S ratio of 4.03 reflects strong revenue multiples. The companys return on equity (RoE) stands at 56.70%, highlighting efficient profitability and strong shareholder value creation.

Based on the intersection of technical and fundamental data, GENI is expected to maintain its upward trajectory in the near term, supported by its position above key moving averages. However, the high P/E and P/B multiples suggest caution, as valuations may be stretched. The strong RoE and stable ATR indicate continued profitability and low volatility, making GENI an attractive candidate for investors seeking exposure to Swedens IT consulting sector.

Additional Sources for GENI Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

GENI Stock Overview

Market Cap in USD 74m
Sector Technology
Industry Software - Application
GiC Sub-Industry IT Consulting & Other Services
IPO / Inception

GENI Stock Ratings

Growth Rating 52.4
Fundamental 80.0
Dividend Rating 73.5
Rel. Strength 14.8
Analysts -
Fair Price Momentum 61.98 SEK
Fair Price DCF 35.94 SEK

GENI Dividends

Dividend Yield 12m 2.72%
Yield on Cost 5y 7.63%
Annual Growth 5y 37.97%
Payout Consistency 98.0%

GENI Growth Ratios

Growth Correlation 3m 13.4%
Growth Correlation 12m 67.6%
Growth Correlation 5y 25.9%
CAGR 5y 25.47%
CAGR/Max DD 5y 0.34
Sharpe Ratio 12m -0.13
Alpha 19.29
Beta 0.634
Volatility 33.67%
Current Volume 12.2k
Average Volume 20d 11.4k
What is the price of GENI stocks?
As of May 09, 2025, the stock is trading at SEK 61.40 with a total of 12,231 shares traded.
Over the past week, the price has changed by +3.19%, over one month by +9.84%, over three months by +16.73% and over the past year by +26.55%.
Is Generic Sweden publ a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Generic Sweden publ (ST:GENI) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 80.03 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GENI as of May 2025 is 61.98. This means that GENI is currently overvalued and has a potential downside of 0.94%.
Is GENI a buy, sell or hold?
Generic Sweden publ has no consensus analysts rating.
What are the forecast for GENI stock price target?
According to ValueRays Forecast Model, GENI Generic Sweden publ will be worth about 68.9 in May 2026. The stock is currently trading at 61.40. This means that the stock has a potential upside of +12.23%.
Issuer Forecast Upside
Wallstreet Target Price 5.6 -91%
Analysts Target Price - -
ValueRay Target Price 68.9 12.2%